GBT Stock Overview
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Guerbet SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €35.85 |
| 52 Week High | €36.00 |
| 52 Week Low | €15.48 |
| Beta | 0.75 |
| 1 Month Change | 4.67% |
| 3 Month Change | 84.60% |
| 1 Year Change | 119.40% |
| 3 Year Change | 2.87% |
| 5 Year Change | -32.36% |
| Change since IPO | 260.87% |
Recent News & Updates
Further Upside For Guerbet SA (EPA:GBT) Shares Could Introduce Price Risks After 48% Bounce
Feb 29
Returns On Capital At Guerbet (EPA:GBT) Paint A Concerning Picture
Feb 11Recent updates
Further Upside For Guerbet SA (EPA:GBT) Shares Could Introduce Price Risks After 48% Bounce
Feb 29Returns On Capital At Guerbet (EPA:GBT) Paint A Concerning Picture
Feb 11Guerbet SA (EPA:GBT) Screens Well But There Might Be A Catch
Jan 15The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence
Jul 22Guerbet SA's (EPA:GBT) Intrinsic Value Is Potentially 92% Above Its Share Price
Jul 27Analysts Have Been Trimming Their Guerbet SA (EPA:GBT) Price Target After Its Latest Report
Mar 28Is Guerbet (EPA:GBT) A Risky Investment?
Oct 25The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence
Sep 23Is Now The Time To Look At Buying Guerbet SA (EPA:GBT)?
May 27We Think Guerbet (EPA:GBT) Is Taking Some Risk With Its Debt
May 04Is Guerbet SA (EPA:GBT) A Good Fit For Your Dividend Portfolio?
Apr 05Guerbet SA's (EPA:GBT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Mar 19What Type Of Shareholders Make Up Guerbet SA's (EPA:GBT) Share Registry?
Mar 01When Should You Buy Guerbet SA (EPA:GBT)?
Feb 10
How Much Did Guerbet's(EPA:GBT) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 28Guerbet SA (EPA:GBT) Shares Could Be 25% Above Their Intrinsic Value Estimate
Jan 13Would Guerbet SA (EPA:GBT) Be Valuable To Income Investors?
Dec 23We Think Guerbet's (EPA:GBT) Statutory Profit Might Understate Its Earnings Potential
Dec 11Do Its Financials Have Any Role To Play In Driving Guerbet SA's (EPA:GBT) Stock Up Recently?
Nov 27Shareholder Returns
| GBT | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | 8.5% | -1.3% | -0.2% |
| 1Y | 119.4% | 11.1% | 2.4% |
Return vs Industry: GBT exceeded the French Medical Equipment industry which returned 11.5% over the past year.
Return vs Market: GBT exceeded the French Market which returned 4% over the past year.
Price Volatility
| GBT volatility | |
|---|---|
| GBT Average Weekly Movement | 7.1% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: GBT's share price has been volatile over the past 3 months.
Volatility Over Time: GBT's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1926 | 2,920 | David Hale | www.guerbet.com |
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services.
Guerbet SA Fundamentals Summary
| GBT fundamental statistics | |
|---|---|
| Market cap | €450.92m |
| Earnings (TTM) | €23.87m |
| Revenue (TTM) | €795.65m |
18.9x
P/E Ratio0.6x
P/S RatioIs GBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GBT income statement (TTM) | |
|---|---|
| Revenue | €795.65m |
| Cost of Revenue | €206.19m |
| Gross Profit | €589.47m |
| Other Expenses | €565.60m |
| Earnings | €23.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 25, 2024
| Earnings per share (EPS) | 1.90 |
| Gross Margin | 74.09% |
| Net Profit Margin | 3.00% |
| Debt/Equity Ratio | 96.4% |
How did GBT perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield26%
Payout RatioDoes GBT pay a reliable dividends?
See GBT dividend history and benchmarks| Guerbet dividend dates | |
|---|---|
| Ex Dividend Date | Jul 01 2024 |
| Dividend Pay Date | Jul 03 2024 |
| Days until Ex dividend | 66 days |
| Days until Dividend pay date | 68 days |
Does GBT pay a reliable dividends?
See GBT dividend history and benchmarks